About
Epitomee medical is a public company developing and commercializing ingestible therapeutic devices, aimed to tackle some of today’s most prevalent chronic diseases with a self-managed, safer, kinder to the system and more manageable way.
Epitomee’s groundbreaking platform technology is based on self-expanding hydro-gel scaffolds folded into a standard pharmaceutical capsule, produced from biocompatible excipients, food additives, and food contact materials. Epitomee’s hydro-gel scaffolds can be engineered to be triggered by different zone-specific pH levels, allowing the allocation of an indication-specific deployment region for every product to enable an optimal therapeutic effect.
Funding history · 3 rounds · $77.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Epitomee Medical become a public company and on which exchange?
- Epitomee Medical became a public company on the TASE (Tel Aviv Stock Exchange) in December 2021, with a valuation of $203 million.
- What was the outcome of Epitomee Medical's partnership with Nestlé Health Science regarding the weight loss capsule?
- In November 2023, Nestlé Health Science canceled its agreement to market Epitomee Medical's weight loss pill, leading to a significant drop in Epitomee's stock.
- What was a key development for Epitomee Medical's weight management device in September 2024?
- In September 2024, Epitomee Medical announced that its capsule weight management device received FDA clearance.
- What were the results of the RESET Study for Epitomee Medical's drug-free capsule, as presented in November 2024?
- In November 2024, results from the RESET Study for Epitomee Medical's drug-free capsule, which helps patients shed pounds, were presented at ObesityWeek® 2024.
- What was the status of Epitomee Medical's weight loss capsule pivotal study with Nestlé Health Science in March 2023?
- In March 2023, Epitomee Medical and Nestlé Health Science announced the completion of patient enrollment in Epitomee's weight loss capsule pivotal study in the United States.
- What was the most recent funding round for Epitomee Medical prior to its IPO?
- Epitomee Medical closed an $8 million equity financing round in April 2019, with XT Venture Capital as a lead investor.
- What is the primary focus of Epitomee Medical's technology platform?
- Epitomee Medical's platform technology is based on self-expanding hydro-gel scaffolds, folded into a standard pharmaceutical capsule, designed to tackle chronic diseases with ingestible therapeutic devices.
- What is the current employee count for Epitomee Medical?
- Epitomee Medical currently has 32 employees.